Drug intelligence / Profile preview

PBF-4883

Development stage: Preclinical
Lead developer: Palobiofarma
Modality: Small Molecules

Overview

PBF-4883 is a small molecule drug that acts as an inhibitor of SLC29A1, also known as equilibrative nucleoside transporter 1 (ENT1). SLC29A1 is involved in the facilitative transport of nucleosides and nucleobases, contributing to their cellular homeostasis. By inhibiting this transporter, PBF-4883 may modulate extracellular and intracellular levels of nucleosides such as adenosine, guanosine, inosine, uridine, thymidine, and cytidine. The drug is being developed primarily for the treatment of neoplasms (cancers) and remains in preclinical development. The originator and active developer is Palobiofarma SL[1].

Targets

ENT1 (Solute carrier family 29 member 1)

Beyond the preview

Go deeper on PBF-4883.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBF-4883.

Explore the full profile